TriSalus Life Sciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $45.2M | $29.4M | $18.5M | $12.4M | — |
| Cost of Revenue | — | $7.0M | $4.1M | $2.6M | $2.3M | — |
| Gross Profit | — | $38.2M | $25.3M | $15.9M | $10.1M | — |
| Gross Margin | — | 84.6% | 86.1% | 85.9% | 81.8% | — |
| Operating Expenses | ||||||
| Research & Development | — | $15.0M | $17.7M | $29.8M | $21.4M | — |
| SG&A Expense | — | $21.5M | $18.0M | $23.5M | $12.5M | $3.0M |
| Operating Income | — | $-26.9M | $-36.2M | $-54.5M | $-36.4M | $-3.0M |
| Operating Margin | — | -59.7% | -122.9% | -294.3% | -293.9% | — |
| Interest Expense | — | — | — | $16.0K | $1.0K | — |
| Pretax Income | — | $-39.2M | $-30.0M | $-59.4M | $-47.2M | $4.8M |
| Income Tax Expense | — | $7.0K | $6.0K | $9.0K | $9.0K | $0 |
| Net Income | — | $-39.2M | $-30.0M | $-59.4M | $-47.2M | $4.8M |
| Net Margin | — | -86.9% | -102.1% | -320.7% | -380.6% | — |
| EPS (Basic) | — | $-1.84 | $-1.31 | $-2.26 | $-1.80 | — |
| EPS (Diluted) | — | $-1.84 | $-1.31 | $-2.26 | $-1.80 | — |
| Shares Outstanding (Basic) | 61.3M | 37.9M | 25.3M | 28.2M | 27.9M | — |
| Shares Outstanding (Diluted) | 61.3M | 37.9M | 25.3M | 28.2M | 27.9M | — |
| Dividends Per Share | — | — | — | — | — | — |